LANOXIN PEDIATRIC
Details
- Status
- Prescription
- First Approved
- 1954-11-16
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
LANOXIN PEDIATRIC Approval History
What LANOXIN PEDIATRIC Treats
2 indicationsLANOXIN PEDIATRIC is approved for 2 conditions since its original approval in 1954. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Heart Failure
- Atrial Fibrillation
Drugs Similar to LANOXIN PEDIATRIC
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LANOXIN PEDIATRIC FDA Label Details
ProIndications & Usage
FDA Label (PDF)1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. Increasing myocardial contractility in pediatric patients with heart failure. Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emerge...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.